Drug Database
LA

lamotrigine orally disintegrating tablet (lamotrigine ODT / lamictal ODT / EUR1048)

✓ Approved

Adare Pharma Solutions · SCN1A · Small Molecule

What is lamotrigine orally disintegrating tablet?

lamotrigine orally disintegrating tablet is a small molecule developed by Adare Pharma Solutions. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand Nameslamotrigine ODT, lamictal ODT, EUR1048
CompanyAdare Pharma Solutions
Drug ClassSmall Molecule
Molecular TargetSCN1A, SCN2A, SCN3A
RouteOral (PO)
StatusApproved
Sources: ClinicalTrials.gov, Adare Pharma Solutions

Mechanism of Action

Molecular Targets

lamotrigine orally disintegrating tablet acts on 3 molecular targets:

SCN1Asodium voltage-gated channel alpha subunit 1 (DEE6B, FEB3)
SCN2Asodium voltage-gated channel alpha subunit 2 (Na(v)1.2, BFNIS)
SCN3Asodium voltage-gated channel alpha subunit 3 (Nav1.3, NAC3)
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.

Therapeutic Indications

lamotrigine orally disintegrating tablet is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Nervous system disordersGeneralised tonic-clonic seizure✓ Approved
Nervous system disordersLennox-Gastaut syndrome✓ Approved
Psychiatric disordersBipolar disorder✓ Approved
Nervous system disordersPartial seizures✓ Approved

Related Research Articles

PubMedClinical ophthalmology (Auckland, N.Z.)2026-08-25

Binocular Visual Function in Children Wearing Single-Vision or Highly Aspherical Lenslet Spectacle Lenses Assessed with a Tablet-Based Dichoptic Platform.

Wu Zhuotong Z, Ye Yuhao Y, Ma Yong Y, Sun Bingqing B et al.

To evaluate multi-distance binocular visual function in children using a tablet-based dichoptic platform and compare performance between single-vision and highly aspherical lenslet (HAL) spectacle lenses. This cross-sectional study included 300 children aged 4 to 17 years wearing single-vision spectacle lenses (n = 154) or HAL spectacle lenses (n = 146). Outcomes included foveal simultaneous-perception non-composite responses, peripheral simultaneous-perception non-normal responses, and fine, dynamic, and gross stereopsis from 0.4 to 3.0 m. Generalized estimating equations clustered by participant evaluated lens type and testing distance, with adjustment for age, sex, myopia magnitude, interocular spherical-equivalent difference, and mean absolute cylinder. Fine stereopsis declined significantly as testing distance increased and was rarely measurable at 2.0 m. Compared with 0.4 m, the adjusted odds of measurable fine stereopsis were lower at 1.5 m (adjusted odds ratio [aOR] = 0.81; P = 0.003) and 2.0 m (aOR = 0.08; P < 0.001). In adjusted observational analyses, HAL lens wear was associated with higher odds of measurable dynamic (aOR = 1.68; P = 0.024) and gross stereopsis (aOR = 2.51; P = 0.006) than single-vision lens wear. Fine stereopsis remained comparable between the two groups (aOR = 0.99; P = 0.960). Foveal non-composite responses were uncommon at 0.4 m but highly prevalent at 3.0 m (>87%) regardless of lens type, while peripheral simultaneous perception remained mostly normal. Tablet-based binocular visual performance declined as the testing distance increased. In this cross-sectional observational analysis, children wearing HAL spectacle lenses showed higher adjusted odds of measurable dynamic and gross stereopsis than those wearing single-vision lenses, while fine stereopsis remained comparable. These findings provide preliminary clinical evidence regarding binocular visual performance with HAL lens wear and warrant confirmation in longitudinal studies across different myopia levels.

PMID 42639154
Read full article →
PubMedScientific reports2026-08-25

Effectiveness of an interactive music tablet intervention to reduce procedural anxiety in children: a randomized controlled trial.

Imle Roland R, Wiemer Ann-Sophie AS, Hartwig Katharina K, Hillebrenner Christiane C et al.

Procedural anxiety in children is common and associated with maladaptive behavior, reduced cooperation, and increased perioperative stress. Although music-based interventions show promise, few are designed for routine clinical care. We evaluated an interactive tablet-based music intervention ("MuMa") for reducing procedural anxiety in children aged 3-11 undergoing elective surgery. We conducted a single-center, parallel-group, randomized controlled trial including 80 children undergoing elective surgery and their caregivers. Participants were randomized to receive the MuMa intervention preoperatively or standard care. Primary outcomes were child (modified Yale Preoperative Anxiety Scale) and caregiver anxiety (State-Trait Anxiety Inventory), assessed before and after the intervention. Secondary outcomes included heart rate variability, compliance during anesthesia induction, postoperative agitation, and behavioral changes at 1, 4, and 12 weeks post-procedure. Trial registration: German Clinical Trials Registry (DRKS00027873), registered 13 May 2022. Here we show that the intervention reduces preoperative anxiety by 38% (standardized mean difference -0.8; 95% CI -1.2 to -0.3) and integrates readily into routine perioperative workflows. Effects are greatest in children with high baseline anxiety (SMD -1.7; 95% CI -2.8 to -0.5) and in those aged 3-6 years (SMD -0.9; 95% CI -1.5 to -0.3). No clinically relevant differences are observed for secondary outcomes. This interactive music intervention significantly reduces procedural anxiety in children, particularly among younger participants and those with high baseline anxiety. Its low resource requirements and ease of implementation support its potential as a scalable non-pharmacological strategy in pediatric perioperative care. Further research should evaluate its generalizability across diverse settings.

PMID 42637802
Read full article →
PubMedFrontiers in immunology2026-08-25

Modulating glutamate neurotransmission in in vivo models of Multiple Sclerosis: a narrative review.

Stamoula Eleni E, Vavilis Theofanis T, Boskou Ioanna I, Vampertzi Olga O et al.

Glutamate (Glu), the primary excitatory neurotransmitter of the central and peripheral nervous systems, plays essential roles in cognition, synaptic plasticity, and immune modulation. Its dysregulation is increasingly recognized as a component of neuroinflammation and neurodegeneration in multiple sclerosis (MS). In MS and its principal experimental model, experimental autoimmune encephalomyelitis (EAE), impaired Glu homeostasis leads to excitotoxicity, calcium overload, and oxidative damage, compounded by proinflammatory mediators such as TNF-α. This makes glutamatergic receptors, transporters, and related signaling pathways candidate therapeutic targets that warrant systematic preclinical evaluation. To assess the preclinical evidence base for agents targeting these pathways, we conducted a systematic literature search, we conducted a systematic literature search and comparatively assessed published in vivo studies examining the effects of glutamatergic agents in EAE models, applying predefined inclusion and exclusion criteria Across the reviewed EAE studies, glutamatergic agents were frequently reported to delay disease onset, alleviate clinical symptoms, attenuate neuroinflammation, and reduce demyelination, although effect sizes and reproducibility varied across models, dosing regimens and treatment timing. Collectively, these data indicate that pharmacological modulation of glutamatergic signaling can engage multiple facets of EAE pathophysiology. However, completed clinical trials of repurposed glutamatergic drugs (riluzole, amantadine, memantine, lamotrigine) have so far failed to demonstrate disease-modifying efficacy in MS, underscoring a marked translational gap.

PMID 42639338
Read full article →
PubMedRSC advances2026-08-25

Spectrophotometric determination of levofloxacin using bromophenol blue: insight into the structure of the formed supramolecular complex.

Nashat Nancy W NW, Eldawy Heba G HG, Abdel-Kader Nora S NS, Mostafa Gamal A E GAE et al.

Levofloxacin was determined using a spectrophotometric method based on the formation of a hydrogen-bonded supramolecular complex with bromophenol blue. The method was linear over 1-20 µg mL-1, with a limit of detection of 0.39 µg mL-1. It was successfully applied to commercial tablet formulations (250, 500, and 750 mg), yielding recoveries of 98.80-100.69%. Interference studies confirmed high selectivity toward common pharmaceutical excipients with recoveries ranging from 97.50-101.48% and RSD values below 1.57%. Greenness assessment using AGREE, Eco-scale, and White Analytical Chemistry (WAC) metrics demonstrated good environmental compatibility. Quantum chemical calculations were performed to get an insight into the nature of the formed supramolecular complex. The optimized structure demonstrated that two inter- and intramolecular hydrogen bonds stabilize the formed complex. NBO analysis confirmed the presence of charge transfer between levofloxacin and bromophenol blue via the carboxylic acid of the drug and one of the phenolic groups of bromophenol blue.

PMID 42639381
Read full article →
PubMedEpileptic disorders : international epilepsy journal with videotape2026-08-25

The effect of antiseizure medications on the exposure to combined oral contraceptives: A systematic review and network meta-analysis.

Cohen Hagar H, Mahajna Amnah Omar AO, Ben-Shushan Tomer T, Matok Ilan I et al.

Current recommendations for prescribing combined oral contraceptives (COCs) to people with epilepsy are often conflicting, particularly for weak inducers of cytochrome P450 3A4. We aimed to critically review the literature and compare the antiseizure medication (ASM)-induced changes in exposure to COC components. In this systematic review and network meta-analysis (PROSPERO: CRD42024513792), in accordance with PRISMA 2015/2020, we searched PubMed, EMBASE, Cochrane, and FDA documents up to January 2026. Eligible studies were clinical trials assessing induction (≥ 5 days) of ethinylestradiol combined with progestins by ASMs. The areas under the concentration-time curve (AUC) of individual hormones with/without the ASM were indirectly compared. The point estimate was the standardized mean difference (SMD; significant when the 95% confidence interval does not encompass zero). Bias risk was assessed using the PKclin tool. The 17 studies (16 reports) involving 399 individuals and 15 ASMs were all conducted with COCs containing the two progestins least sensitive to enzyme induction and ≥ 30 μg ethinylestradiol. Nine ASMs were studied at doses 13-75% lower than the recommended maximum (median 50%). Brivaracetam (100 mg/day) reduced the exposure to ethinylestradiol more than 1000 mg/day levetiracetam (SMD -10; 95% confidence interval - 0.20-0). The effects of 300 mg/day lamotrigine on ethinylestradiol and levonorgestrel were greater than those of 400 mg/day lacosamide (0.18; 0.11-0.25, 0.28; 0.20-0.37). Low-dose (50 mg/day) and high-dose (200 mg/day) topiramate were comparable in their effects on ethinylestradiol and norethindrone, and the low dose did not differ from weak inducers in altering ethinylestradiol exposure. Current recommendations may underestimate ASM effects on exposure to COC components, especially those in newer COCs. Greater caution is recommended with low-dose topiramate. For individuals treated with weak COC inducers without additional contraceptive means, COCs containing levonorgestrel or norethindrone might be preferable given their lower vulnerability to induction.

PMID 42640179
Read full article →
PubMedFamily practice2026-08-25

Validation of an artificial intelligence-based drawing platform against the Clock Drawing Test for cognitive screening: a comparative study between Alzheimer's disease and healthy controls.

Sur Ünal Ülkü Ü, Karabaş Halil Alper HA, Yadigar Aybora A, Turnalı Ahsen Simanur AS et al.

Traditional manual Clock Drawing Tests (CDTs) are widely used for cognitive screening but are constrained by human subjectivity and alphanumeric literacy or cultural barriers. This study validated an open-source artificial intelligence (AI)-based drawing platform utilizing universal, pre-linguistic Lea symbols against manual CDT metrics for cognitive screening and differentiating Alzheimer's disease (AD) from healthy controls (HCs). In this cross-sectional validation study, 111 participants aged ≥65 years, 55 clinically diagnosed AD patients and 56 HCs, were evaluated. Participants completed manual CDTs (6-point and 10-point scoring) and the AI-based drawing task on a tablet. Diagnostic accuracy was evaluated using receiver operating characteristic curve analysis, Cohen's kappa (κ), and multivariable logistic regression adjusted for age and gender. The AI model demonstrated clear diagnostic accuracy (area under the curve = 0.868), with overall accuracy comparable to the 10-point manual scale. An optimal diagnostic cut-off of <27.00 points, identified in this study, achieved 83.6% sensitivity and 75.0% specificity, demonstrating substantial agreement with clinical diagnosis (κ = 0.586, P < 0.001). Crucially, the AI-based drawing platform flagged 14 HCs (25.0%) as at-risk who were classified as intact by conventional manual CDT scales. Multivariable regression confirmed the AI score as a powerful independent predictor of AD status after adjusting for demographics (odds ratio: 0.940, 95% confidence interval: 0.904-0.979, P < 0.001). The AI-based drawing platform provides an objective, automated alternative to traditional CDTs. Its sensitivity to subtle visuoconstructional variations positions it as an effective, low-cost triage tool to optimize early neurological referrals in primary care.

PMID 42639755
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about lamotrigine orally disintegrating tablet